Join
Live feed
·
PRReleasevia Quantisnow
Biohaven Ltd. logo

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

ByQuantisnow·Wall Street's wire, on your screen.
BHVN· Biohaven Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BHVN (Biohaven Ltd.) and more on Quantisnow.